Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating ...

Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia ...

Glargine U300 use was common, especially with increased CKD stages and baseline HbA1c levels among patients with type 2 diabetes.

inhibitor licensed by Fosun Pharma Industrial from Ardelyx, Inc. In October 2023, Tenapanor was approved by the US Food and Drug Administration to reduce serum phosphorus in adults with CKD on ...

Maxim analyst Naz Rahman lowered the firm’s price target on scPharmaceuticals (SCPH) to $12 from $20 but keeps a Buy rating on the shares after ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

The National Kidney Foundation (NKF) is proud to announce that its KidneyCARE (Community Access to Research Equity)™ Study – ...

Vani Manja, country managing director and head of human pharma at BI UK and Ireland said: “The SPOT CKD programme and the establishment of these collaborative working projects marks an important step ...

Increased antibiotic use can lead, seemingly paradoxically, to more problematic infections, as the bacteria evolve to resist ...

AKI and CKD affect millions worldwide, with AKI accounting for a significant proportion of hospital and intensive care unit admissions. The sudden decline in kidney function leads to severe ...